$NTRB
NutriBand Inc. Stock $ntrb

$ntrb Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000121390022054592 Filed on September 08, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$456.1K	$477.9K	$491.9K
YoY Change	113.41%	10.25%	41.31%
Cost Of Revenue	$304.4K	$277.4K	$388.5K
YoY Change	62.96%	41.83%	140.24%
Gross Profit	$151.8K	$200.5K	$103.4K
YoY Change	462.62%	-15.72%	-44.54%
Gross Profit Margin	33.28%	41.95%	21.01%
Selling, General & Admin	$908.2K	$768.6K	$1.447M
YoY Change	78.35%	39.25%	-38.89%
% of Gross Profit	598.29%	383.35%	1400.3%
Research & Development	$277.9K	$117.8K	$250.4K
YoY Change
% of Gross Profit	183.05%	58.76%	242.26%
Depreciation & Amortization	$78.67K	$77.48K	$152.9K
YoY Change	-1.12%	1.6%	99.76%
% of Gross Profit	51.83%	38.65%	147.96%
Operating Expenses	$908.2K	$886.4K	$1.698M
YoY Change	78.35%	60.59%	-28.31%
Operating Profit	-$1.034M	-$685.9K	-$1.594M
YoY Change	114.47%	118.38%	-26.93%
Interest Expense	-$4.430K	-$4.110K	-$3.150K
YoY Change	-89.2%	-89.94%	-95.73%
% of Operating Profit
Other Income/Expense, Net	-$4.429K	-$4.110K
YoY Change	-88.25%
Pretax Income	-$1.039M	-$690.0K	-$3.768M
YoY Change	99.78%	119.0%	67.32%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$1.039M	-$690.0K	-$3.768M
YoY Change	99.78%	119.0%	67.32%
Net Earnings / Revenue	-227.71%	-144.37%	-766.11%
Basic Earnings Per Share	-$0.12	-$0.08
Diluted Earnings Per Share	-$0.12	-$75.14K	-$434.3K
COMMON SHARES
Basic Shares Outstanding	8.409M shares	9.183M shares
Diluted Shares Outstanding	8.409M shares	9.183M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.345M	$4.011M	$4.892M
YoY Change	999.24%	876.42%	3118.55%
Cash & Equivalents	$3.345M	$4.011M	$4.892M
Short-Term Investments
Other Short-Term Assets	$461.0K	$404.6K	$370.5K
YoY Change	113.3%	43.22%
Inventory	$161.8K	$127.5K	$131.7K
Prepaid Expenses	$461.0K		$370.5K
Receivables	$146.6K	$99.10K	$71.38K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.114M	$4.642M	$5.465M
YoY Change	578.03%	396.8%	1639.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$978.9K	$1.099M	$998.3K
YoY Change	-5.43%	2.56%	-7.27%
Goodwill	$5.349M		$5.349M
YoY Change
Intangibles	$862.0K		$926.9K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$7.273M	$7.343M	$7.274M
YoY Change	-23.9%	-23.72%	-24.33%
TOTAL ASSETS
Total Short-Term Assets	$4.114M	$4.642M	$5.465M
Total Long-Term Assets	$7.273M	$7.343M	$7.274M
Total Assets	$11.39M	$11.98M	$12.74M
YoY Change	12.04%	13.49%	28.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$620.9K	$535.4K	$639.5K
YoY Change	-36.36%	-38.74%	-32.01%
Accrued Expenses	$19.53K	$33.89K	$19.33K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Long-Term Debt Due	$17.62K	$23.75K	$14.12K
YoY Change	-87.38%	-82.94%	-89.81%
Total Short-Term Liabilities	$803.9K	$723.1K	$779.3K
YoY Change	-69.73%	-71.33%	-69.66%
LONG-TERM LIABILITIES
Long-Term Debt	$115.8K	$115.8K	$101.1K
YoY Change	-39.69%	-42.7%	-59.04%
Other Long-Term Liabilities	$65.57K	$65.57K
YoY Change
Total Long-Term Liabilities	$181.3K	$181.3K	$101.1K
YoY Change	-5.53%	-10.23%	-59.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$803.9K	$723.1K	$779.3K
Total Long-Term Liabilities	$181.3K	$181.3K	$101.1K
Total Liabilities	$985.2K	$904.4K	$880.4K
YoY Change	-65.4%	-66.8%	-68.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.74M		-$18.01M
YoY Change
Common Stock	$7.803K		$9.155K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$130.1K		$104.5K
YoY Change
Treasury Stock Shares	39.88K shares		32.81K shares
Shareholders Equity	$10.40M	$11.08M	$11.86M
YoY Change
Total Liabilities & Shareholders Equity	$11.39M	$11.98M	$12.74M
YoY Change	12.04%	13.49%	28.33%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.039M	-$690.0K	-$3.768M
YoY Change	99.78%	119.0%	67.32%
Depreciation, Depletion And Amortization	$78.67K	$77.48K	$152.9K
YoY Change	-1.12%	1.6%	99.76%
Cash From Operating Activities	-$908.5K	-$744.3K	-$2.441M
YoY Change	926.31%	166.36%	2836.0%
INVESTING ACTIVITIES
Capital Expenditures	-$24.21K	-$43.80K	-$32.20K
YoY Change	127.97%	12.94%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$24.21K	-$43.80K	-$32.20K
YoY Change	127.97%	12.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$8.675M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	266.6K	-93.16K	7.061M
YoY Change	-3727.35%	-116.15%	16816.82%
NET CHANGE
Cash From Operating Activities	-908.5K	-744.3K	-2.441M
Cash From Investing Activities	-24.21K	-43.80K	-32.20K
Cash From Financing Activities	266.6K	-93.16K	7.061M
Net Change In Cash	-666.1K	-881.2K	4.588M
YoY Change	525.5%	-440.55%	-11178.48%
FREE CASH FLOW
Cash From Operating Activities	-$908.5K	-$744.3K	-$2.441M
Capital Expenditures	-$24.21K	-$43.80K	-$32.20K
Free Cash Flow	-$884.3K	-$700.5K	-$2.409M
YoY Change	1035.15%	191.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2022Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset		usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	ntrb	Purchase Of Treasury Stock PurchaseOfTreasuryStock		usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q3	dei	Document Period End Date DocumentPeriodEndDate	2022-07-31
CY2022Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32801
CY2022Q3	dei	City Area Code CityAreaCode	(407)
CY2022Q3	dei	Local Phone Number LocalPhoneNumber	377-6695
CY2022Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q3	dei	Entity File Number EntityFileNumber	000-55654
CY2022Q3	dei	Entity Registrant Name EntityRegistrantName	NUTRIBAND INC.
CY2022Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-1118176
CY2022Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	121 South Orange Ave
CY2022Q3	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1500
CY2022Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Orlando
CY2022Q3	dei	Document Type DocumentType	10-Q
CY2022Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2022Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q3	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022Q3	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7803263	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3344558	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4891868	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	146557	usd
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	71380	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	161830	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	131648	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	461011	usd
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	370472	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	4113956	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	5465368	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	978863	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	979297	usd
CY2022Q3	us-gaap	Goodwill Goodwill	5349039	usd
CY2022Q1	us-gaap	Goodwill Goodwill	5349039	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	83210	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19043	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	862004	usd
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	926913	usd
CY2022Q3	us-gaap	Assets Assets	11387072	usd
CY2022Q1	us-gaap	Assets Assets	12739660	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	620861	usd
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	639539	usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	145914	usd
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	106267	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	19526	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	19331	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	17623	usd
CY2022Q1	us-gaap	Notes Payable Current NotesPayableCurrent	14119	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	803924	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	779256	usd
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	115749	usd
CY2022Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	101119	usd
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	65569	usd
CY2022Q3	us-gaap	Liabilities Liabilities	985242	usd
CY2022Q1	us-gaap	Liabilities Liabilities	880375	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	291666666	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	291666666	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7843146	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9187659	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7803263	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9154846	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	7803	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	9155	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30264359	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	29966132	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-304	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-304	usd
CY2022Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	39883	shares
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	32813	shares
CY2022Q3	us-gaap	Treasury Stock Value TreasuryStockValue	130133	usd
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	104467	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19739895	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18011231	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	10401830	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	11859285	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11387072	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12739660	usd
CY2022Q3	us-gaap	Revenues Revenues	456149	usd
CY2021Q3	us-gaap	Revenues Revenues	213739	usd
	us-gaap	Revenues Revenues	934071	usd
	us-gaap	Revenues Revenues	647227	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	304353	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	214455	usd
	us-gaap	Cost Of Revenue CostOfRevenue	581789	usd
	us-gaap	Cost Of Revenue CostOfRevenue	409606	usd
CY2022Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	277869	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	395683	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	908173	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	481526	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1676724	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1034827	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	1490395	usd
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	695981	usd
	us-gaap	Costs And Expenses CostsAndExpenses	2654196	usd
	us-gaap	Costs And Expenses CostsAndExpenses	1444433	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1034246	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-482242	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1720125	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-797206	usd
CY2021Q3	ntrb	Gain On Forgiveness Of Debt GainOnForgivenessOfDebt	3338	usd
	ntrb	Gain On Forgiveness Of Debt GainOnForgivenessOfDebt	43214	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	4429	usd
CY2021Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	41019	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	8539	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	81888	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4429	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-37681	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8539	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38674	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1038675	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-519923	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1728664	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-835880	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-1038675	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-519923	usd
	us-gaap	Profit Loss ProfitLoss	-1728664	usd
	us-gaap	Profit Loss ProfitLoss	-835880	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.2
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8409141	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7415647	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8779933	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7400355	shares
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1038675	usd
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-519923	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1728664	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-835880	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1038675	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-519923	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1728664	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-835880	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	11859285	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	296875	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	93100	usd
	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	-118766	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1728664	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	10401830	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	7111946	usd
	ntrb	Stock Issued During Period Common Stock Issued For Proceeds And Payment For License StockIssuedDuringPeriodCommonStockIssuedForProceedsAndPaymentForLicense	640000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	400000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-835880	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	7316066	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	11080110	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	296875	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	93100	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	-29580	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1038675	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	10401830	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	7835989	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-519923	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	7316066	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1728664	usd
	us-gaap	Net Income Loss NetIncomeLoss	-835880	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	156146	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	155822	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	73108	usd
	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	29967	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	43214	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	93100	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	225000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	75177	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-95582	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	90539	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	41127	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	30182	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	19752	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	39647	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-22142	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-28370	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-18678	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	44659	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1652750	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-367944	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	68009	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	49396	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-68009	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49396	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	583000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	296875	usd
	ntrb	Payment On Note Payable PaymentOnNotePayable	4660	usd
	ntrb	Payment On Note Payable PaymentOnNotePayable	1213	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	12182	usd
	ntrb	Purchase Of Treasury Stock PurchaseOfTreasuryStock	-118766	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	173449	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	569605	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1547310	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	152265	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4891868	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	151993	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3344558	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	304258	usd
	us-gaap	Interest Paid Net InterestPaidNet	8539	usd
	us-gaap	Interest Paid Net InterestPaidNet	4060	usd
	us-gaap	Stock Issued1 StockIssued1	1400	usd
	ntrb	Common Stock Issued For Prepaid Consulting CommonStockIssuedForPrepaidConsulting	400000	usd
	ntrb	Noncash Payment For License Agreement NoncashPaymentForLicenseAgreement	57000	usd
	ntrb	Common Stock Issued For Subscription Payable CommonStockIssuedForSubscriptionPayable	70000	usd
	ntrb	Adoption Of Asc842 Operating Lease Asset And Liability AdoptionOfASC842OperatingLeaseAssetAndLiability	94134	usd
	ntrb	Promissory Note On Equipment Purchase PromissoryNoteOnEquipmentPurchase	32843	usd
CY2018Q3	ntrb	Description Of Acquired DescriptionOfAcquired	On August 1, 2018, the Company acquired 4P Therapeutics LLC (“4P Therapeutics”) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000, and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics.
CY2020Q3	ntrb	Acquired Percentage AcquiredPercentage	1	pure
CY2021Q1	ntrb	License Fee LicenseFee	50000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022Q3	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	3344558	usd
	ntrb	Working Capital WorkingCapital	3310032	usd
	ntrb	Operation Income OperationIncome	1720125	usd
	ntrb	Cash Flow From Operations CashFlowFromOperations	1652750	usd
CY2021Q4	ntrb	Proceeds From Issuances Initial Public Offering ProceedsFromIssuancesInitialPublicOffering	5836230	usd
	ntrb	Proceeds From Warrants Exercises ProceedsFromWarrantsExercises	3239845	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; "><i><span style="text-decoration:underline">Use of Estimates </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; "><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; ">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; "> </p>
CY2022Q3	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1393561	usd
CY2022Q1	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1302758	usd
	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; "><i><span style="text-decoration:underline">Contract Liabilities</span></i></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 2.25pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; ">Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; "><i> </i></p>
	ntrb	Total Revenue TotalRevenue	934071	usd
	ntrb	Total Revenue TotalRevenue	647227	usd
CY2022Q3	ntrb	Total Revenue TotalRevenue	456149	usd
CY2021Q3	ntrb	Total Revenue TotalRevenue	213739	usd
CY2022Q3	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	414698	usd
CY2022Q1	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	323461	usd
CY2022Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	978863	usd
CY2022Q1	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	979297	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	796894	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	541251	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	394904	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	213739	usd
	us-gaap	Cost Of Services Catering CostOfServicesCatering	137177	usd
	us-gaap	Cost Of Services Catering CostOfServicesCatering	105976	usd
CY2022Q3	us-gaap	Cost Of Services Catering CostOfServicesCatering	61245	usd
	ntrb	Total Revenue TotalRevenue	934071	usd
	ntrb	Total Revenue TotalRevenue	647227	usd
CY2022Q3	ntrb	Total Revenue TotalRevenue	456149	usd
CY2021Q3	ntrb	Total Revenue TotalRevenue	213739	usd
	us-gaap	Depreciation Depreciation	91237	usd
	us-gaap	Depreciation Depreciation	90913	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	69845	usd
CY2022Q3	ntrb	Goodwill Value GoodwillValue	1719235	usd
CY2020Q3	ntrb	Goodwill Value GoodwillValue	5810640	usd
CY2022Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2180836	usd
CY2022Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	3629813	usd
CY2022Q3	us-gaap	Goodwill Gross GoodwillGross	5349039	usd
CY2022Q1	us-gaap	Goodwill Gross GoodwillGross	5349039	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	54132	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	64909	usd
CY2022Q3	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1570954	shares
CY2021Q3	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	165468	shares
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	254587	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	862004	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	926913	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; "><i><span style="text-decoration:underline">Reclassification</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: #FDFDFD"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; ">The Company has reclassified prior year amounts to show the allocation of depreciation expense to cost of goods sold.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: #FDFDFD"> </p>
CY2022Q3	ntrb	Fair Value Of Compensation Expense FairValueOfCompensationExpense	93100	usd
CY2022Q2	us-gaap	Option Indexed To Issuers Equity Shares OptionIndexedToIssuersEquityShares	39811	shares
	us-gaap	Stock Issued1 StockIssued1		usd
CY2020Q1	ntrb	Note Payables Description NotePayablesDescription	On March 21, 2020, the Coronavirus Aid Relief and Economic Security Act (“CARES ACT” was enacted. The CARES ACT established the Paycheck Protection Program (“PPP”) which funds small businesses through federally guaranteed loans. Under the PPP, companies are eligible for forgiveness of principal and interest if the proceeds are used for eligible payroll costs, rent and utility costs. On June 17, 2020, the Company’s subsidiary, 4P Therapeutics, was advanced $34,870 under the PPP, all of which was forgiven as of April 30, 2021. The Company recorded a gain on the extinguishment of debt of $34,870 during the six months ended July 31, 2021.
CY2020Q3	us-gaap	Proceeds From Loan Originations1 ProceedsFromLoanOriginations1	100000	usd
CY2021Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	17182	shares
	us-gaap	Line Of Credit Facility Frequency Of Payment And Payment Terms LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms	Active Intelligence, the Company’s newly acquired subsidiary, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000 due October 16, 2029, with interest of 5% per year.
CY2022Q3	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	139184	usd
	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	1697	usd
CY2022	us-gaap	Line Of Credit Facility Periodic Payment Principal LineOfCreditFacilityPeriodicPaymentPrincipal	8344	usd
	ntrb	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	8344	usd
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	3647	usd
CY2022Q3	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	107961	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	10370	usd
CY2022Q2	ntrb	Agreement Purchase Description AgreementPurchaseDescription	the Company entered into a retail installment agreement for the purchase of an automobile. The contract price was $32,274, of which $22,795 was financed. The agreement is for five years bearing interest at 2.95% per annum with payments of $495 per month. The loan is secured by automobile. As of July 31, 2022, the amount due was $21,759 of which $4,325 is current.
	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	The leases mature in 2025 and 2026.
	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.05	pure
CY2022Q1	us-gaap	Loans And Leases Receivable Net Reported Amount LoansAndLeasesReceivableNetReportedAmount	121544	usd
	us-gaap	Interest Expense Other InterestExpenseOther	8539	usd
	us-gaap	Interest Expense Other InterestExpenseOther	81888	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	73108	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	8780	usd
CY2022Q2	us-gaap	Redeemable Noncontrolling Interest Equity Other Carrying Amount RedeemableNoncontrollingInterestEquityOtherCarryingAmount	130133	usd
CY2022Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	296875	usd
CY2022Q3	ntrb	Issuance Of Common Stock IssuanceOfCommonStock	55417	shares
CY2022Q3	ntrb	Cancelled Shares CancelledShares	1400000	shares
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1181500	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1181500	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	319496	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	64009	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	64867	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	129776	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	113109	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	113109	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	113109	usd
CY2022Q3	ntrb	Finite Lived Intangible Asset Amortization Expense After Year Five FiniteLivedIntangibleAssetAmortizationExpenseAfterYearFive	328034	usd
CY2022Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	862004	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	53200	usd
	ntrb	Common Stock Of Description CommonStockOfDescription	On June 25, 2019, the Company effected a one-for-four reverse stock split, pursuant to which each share of common stock became converted into 0.25 shares of common stock, and the Company decreased its authorized common stock from 100,000,000 to 25,000,000 shares.
CY2022Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	35583	shares
CY2022Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	118766	shares
CY2022Q3	ntrb	Issuance Of Common Stock IssuanceOfCommonStock	28583	shares
	us-gaap	Broadcasters License Agreement Commitments Description BroadcastersLicenseAgreementCommitmentsDescription	(a)On February 25, 2021, in connection with the Company’s License Agreement with Rambam, pursuant to a Stock Purchase Agreement with BPM Inno Ltd (“BPM”), the Company issued 94,962 shares of common stock to BPM and received proceeds of $700,000 to be applied to product development expenses under the License Agreement. The Company entered into the Stock Purchase Agreement with BPM in December 2020 and received a payment of $60,000 which is included in Stockholders’ Equity as Subscription Payable in the Company’s consolidated balance sheet as of January 31, 2021. In February 2021, BPM advanced a payment for the Company to Rambam in the amount of $57,000 for the license fee. The balance of the funds of $583,000 was received in February 2021. On February 15, 2021, the Company issued 14,583 shares of common stock, valued at $350,000, for consulting fees in connection with the Rambam License Agreement discussed in Note 8.
CY2021Q1	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	10000	usd
CY2021Q1	ntrb	Subcription Payable Shares SubcriptionPayableShares	1090	shares
CY2021Q3	us-gaap	Revenues Revenues	213739	usd
	us-gaap	Gross Profit GrossProfit	237621	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	-716	usd
	ntrb	Gross Profit Percentages GrossProfitPercentages	0.37	pure
CY2021Q3	ntrb	Gross Profit Percentages GrossProfitPercentages	0	pure
	ntrb	Schedule Of Additional Relating Warrants Outstanding ScheduleOfAdditionalRelatingWarrantsOutstanding	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="font-style: normal; vertical-align: bottom; font-weight: normal"> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-style: normal; font-weight: normal; text-align: center">Range of<br/> Exercise Prices</td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-style: normal; font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid">Number<br/> Outstanding</td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-style: normal; font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining Contractual<br/> Life(Years)</td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-style: normal; font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average<br/> Exercise Price<br/> for Shares<br/> Outstanding</td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-style: normal; font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid">Number<br/> Exercisable</td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-style: normal; font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average<br/> Exercise Price<br/> for Shares<br/> Exercisable</td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-style: normal; font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid">Intrinsic<br/> Value</td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5.36</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">97,534</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">0.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5.36</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">97,534</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5.36</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110"> -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">$</td><td style="text-align: right">12.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,633</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,633</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right">6.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,082,205</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,082,205</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">$</td><td style="text-align: right">4.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">145,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">145,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p>
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	190751	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.26
CY2022	ntrb	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Averages Remaining Contractual Term2 Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAveragesRemainingContractualTerm2Granted	P2Y11M19D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	190751	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	190751	shares
CY2022Q3	ntrb	Exercise Price Outstanding ExercisePriceOutstanding	4.26
	ntrb	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne	P2Y5M23D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	190751	shares
	ntrb	Exercise Price Exercisable ExercisePriceExercisable	4.26
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y5M23D
	ntrb	Schedule Of Option Outstanding ScheduleOfOptionOutstanding	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="font-style: normal; vertical-align: bottom; font-weight: normal"> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-style: normal; font-weight: normal; text-align: center">Range of<br/> Exercise Prices</td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-style: normal; font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid">Number<br/> Outstanding</td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-style: normal; font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average<br/> <span style="font-size: 10pt">Remaining<br/> Contractual<br/> Life(Years)</span></span></td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-style: normal; font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average<br/> <span style="font-size: 10pt">Exercise Price<br/> for Shares<br/> Outstanding</span></span></td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-style: normal; font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid">Number<br/> Exercisable</td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-style: normal; font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average<br/> Exercise Price<br/> for Shares<br/> Exercisable</span></td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"> </td><td style="font-style: normal; font-weight: normal; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-style: normal; font-weight: normal; text-align: center; border-bottom: Black 1.5pt solid">Intrinsic<br/> Value</td><td style="font-style: normal; padding-bottom: 1.5pt; font-weight: normal"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4.58</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">46,666</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">2.48</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">4.58</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">46,666</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">4.58</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141"> -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">$</td><td style="text-align: right">4.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">144,085</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">144,085</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left"> </td></tr> </table>
	ntrb	Gain On Forgiveness Of Debt GainOnForgivenessOfDebt		usd
	us-gaap	Revenues Revenues	934071	usd
CY2022Q3	us-gaap	Revenues Revenues	456149	usd
	us-gaap	Gross Profit GrossProfit	352282	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	151796	usd
	ntrb	Gross Profit Percentages GrossProfitPercentages	0.37	pure
CY2022Q3	ntrb	Gross Profit Percentages GrossProfitPercentages	0.33	pure
	us-gaap	Revenues Revenues	647227	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	1400000	shares
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2025-01-31
	ntrb	Percentage Of Net Income PercentageOfNetIncome	0.035	pure
CY2020Q4	ntrb	Payment For Initial License Fee PaymentForInitialLicenseFee	50000	usd
CY2021Q1	ntrb	Payment For Initial License Fee PaymentForInitialLicenseFee	50000	usd
	us-gaap	Other Commitments Description OtherCommitmentsDescription	The Company had entered into a prior agreement, dated November 13, 2020, with BPM Inno Ltd., Kiryat, Israel (“BPM”), that, in consideration of BPM’s introduction of Rambam to the Company, provided for BPM to have the rights as the exclusive of agent of the Company with Rambam and any other parties similarly introduced by BPM, and for a commission payable to BPM by the Company of 4.5% of revenues received by the Company resulting from the introduction of Rambam (and any other companies as to which the exclusive agency of BPM was in effect), and for BPM’s payment of a royalty to Rambam. If the Company fails to commercialize the medical products subject to the License Agreement with Rambam within 36 months, under the November 13, 2020 agreement, BPM and the Company would share 50/50 in the revenues generated from sales of the licensed products from Rambam. This agreement further provides that it will be effective for a period of 10 years, with either party having the right to terminate on notice given 30 days prior to the desired termination, and also provided for certain territorial distribution rights of BPM as are set forth in the March 10, 2021 Distribution Agreement between the Company and BPM.
	us-gaap	Other Expenses OtherExpenses	232055	usd
CY2022Q3	us-gaap	Deposits Deposits	250000	usd
CY2022Q1	ntrb	Warehouse Space WarehouseSpace	12000	pure
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3000	usd
CY2022Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2025-01-31
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	94134	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022Q3	ntrb	Gain On Forgiveness Of Debt GainOnForgivenessOfDebt		usd
	ntrb	Common Stock Issued For Prepaid Consulting CommonStockIssuedForPrepaidConsulting		usd
	ntrb	Noncash Payment For License Agreement NoncashPaymentForLicenseAgreement		usd
	ntrb	Common Stock Issued For Subscription Payable CommonStockIssuedForSubscriptionPayable		usd
	ntrb	Adoption Of Asc842 Operating Lease Asset And Liability AdoptionOfASC842OperatingLeaseAssetAndLiability		usd
	ntrb	Promissory Note On Equipment Purchase PromissoryNoteOnEquipmentPurchase		usd
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2021Q1	ntrb	Exercise Price Outstanding ExercisePriceOutstanding
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2022	ntrb	Share Based Intrinsic Value Outstanding Beginning Balance ShareBasedIntrinsicValueOutstandingBeginningBalance		usd
CY2022	ntrb	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022	ntrb	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Prices ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices
CY2022	ntrb	Share Based Intrinsic Value Expired Cancelled ShareBasedIntrinsicValueExpiredCancelled		usd
CY2022	ntrb	Stock Issued During Period Shares Stock Options Shares Exercised StockIssuedDuringPeriodSharesStockOptionsSharesExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	ntrb	Share Based Compensation Arrangements By Share Based Payment Remaining Life Exercised ShareBasedCompensationArrangementsByShareBasedPaymentRemainingLifeExercised
CY2022	ntrb	Share Based Intrinsic Value Exercised ShareBasedIntrinsicValueExercised		usd
CY2022Q1	ntrb	Exercise Price Outstanding ExercisePriceOutstanding
CY2022	ntrb	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOne
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022	ntrb	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	ntrb	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Prices ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices
	ntrb	Share Based Intrinsic Value Expired Cancelled ShareBasedIntrinsicValueExpiredCancelled		usd
	ntrb	Stock Issued During Period Shares Stock Options Shares Exercised StockIssuedDuringPeriodSharesStockOptionsSharesExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	ntrb	Share Based Compensation Arrangements By Share Based Payment Remaining Life Exercised ShareBasedCompensationArrangementsByShareBasedPaymentRemainingLifeExercised
	ntrb	Share Based Intrinsic Value Exercised ShareBasedIntrinsicValueExercised		usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022Q3	dei	Amendment Flag AmendmentFlag	false
CY2022Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--01-31
CY2022Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001676047

Files In Submission

Name	View Source	Status
0001213900-22-054592-index-headers.html	Edgar Link	pending
0001213900-22-054592-index.html	Edgar Link	pending
0001213900-22-054592.txt	Edgar Link	pending
0001213900-22-054592-xbrl.zip	Edgar Link	pending
f10q0722ex31-1_nutribandinc.htm	Edgar Link	pending
f10q0722ex31-2_nutribandinc.htm	Edgar Link	pending
f10q0722ex32-1_nutribandinc.htm	Edgar Link	pending
f10q0722_nutribandinc.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10q0722_nutribandinc_htm.xml	Edgar Link	completed
ntrb-20220731.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ntrb-20220731_def.xml	Edgar Link	unprocessable
ntrb-20220731_pre.xml	Edgar Link	unprocessable
ntrb-20220731_lab.xml	Edgar Link	unprocessable
ntrb-20220731_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NTRB
NutriBand Inc. Stock $ntrb

2022 Q3 Form 10-Q Financial Statement

#000121390022054592 Filed on September 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NTRB NutriBand Inc. Stock $ntrb

2022 Q3 Form 10-Q Financial Statement

#000121390022054592 Filed on September 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NTRB
NutriBand Inc. Stock $ntrb